Summary
The provided evaluation content does not contain the specific prescribing-information label text for the weight-management indication, adolescent use, or diabetes/other indications; therefore those claims cannot be verified against the supplied label excerpts. Additionally, the label excerpts supplied focus on thyroid C-cell tumor risk, not the other indication/dosing claims.
Category Scores
Accurate Statements
WEGOVY/semaglutide is associated with a risk of thyroid C-cell tumors (including MTC), as supported by the FDA label.
Supported by Warnings and Precautions (5.1) (rodent thyroid C-cell tumors; human relevance unknown; counsel patients) and Nonclinical Toxicology (13.1) (increased thyroid C-cell adenomas/carcinomas in rodents), and Contraindications (4) referencing MTC/MEN 2.
Unsupported Statements
Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight (with at least one weight-related condition).
No FDA label sections for the approval indications (e.g., Indications and Usage) were provided in the prompt; only thyroid C-cell tumor-related sections (4, 5.1, 13.1) were supplied.
Wegovy is FDA-approved for certain adolescents.
No label excerpts for adolescent indication were provided (e.g., Indications and Usage), so this cannot be verified against the supplied prescribing information.
FDA approval for Wegovy covers chronic weight management, not diabetes treatment.
The supplied label excerpts do not include indication language separating weight management from diabetes treatment; therefore this cannot be supported or contradicted using only the provided label text.
Wegovy is used to help people lose weight and keep it off when combined with diet and exercise.
No label excerpts for diet/exercise in the indications were provided; therefore this cannot be verified against the supplied prescribing information.
Contradictions
Important Omissions
Label evidence (e.g., Indications and Usage section) for adult chronic weight management, adolescent use, and statement that it is not approved for diabetes treatment, as well as any requirement for diet/exercise wording.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-supported claim in the provided content is the thyroid C-cell tumor risk framework; the other indication-related claims are unsupported because relevant label sections were not provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Indication and approval-related claims (adults, adolescents, diabetes exclusion, and diet/exercise phrasing) are not supported by the supplied label excerpts.
Suggested Improvement
Restrict evaluations to the provided label sections (Contraindications 4, Warnings/Precautions 5.1, Nonclinical Toxicology 13.1) or supply the Indications and Usage section text to support/verify the approval-indication and adolescent claims.